Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE versus LABETALOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE versus LABETALOL.
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE vs Labetalol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine is an amide local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. Epinephrine is a vasoconstrictor that prolongs bupivacaine's effect by reducing vascular absorption.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Maximum dose of bupivacaine: 2 mg/kg (not to exceed 175 mg); with epinephrine: 3 mg/kg (not to exceed 225 mg). Administer via local infiltration, peripheral nerve block, epidural, or caudal block. Dose depends on the anesthetic procedure. Repeated doses may be given at intervals of 3-6 hours. Maximum single dose for epidural: 50 mg initially, then 10-25 mg per segment as needed.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
None Documented
Terminal elimination half-life of bupivacaine is approximately 2.7 hours (range 1.5–5.5 hours) in adults. In neonates, half-life is prolonged (8–12 hours) due to immature hepatic function. The half-life of epinephrine is very short (~1–2 minutes) due to rapid metabolism.
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Bupivacaine is primarily metabolized in the liver via CYP3A4 and is excreted renally as metabolites (approximately 95% in urine) and less than 5% unchanged. Epinephrine is rapidly metabolized by COMT and MAO and excreted renally as metabolites.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Category A/B
Category A/B
Alpha/Beta Agonist
Alpha/Beta-Blocker